Apr 10, 2017 12:08 pm UTC| Business
SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies...
Apr 10, 2017 12:08 pm UTC| Business
SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies...
Apr 10, 2017 12:08 pm UTC| Business
SHANGHAI, China and CUPERTINO, Calif., April 10, 2017 -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (CBMG or the Company), a leading clinical-stage biopharmaceutical firm engaged in the development of immunotherapies...
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017 12:08 pm UTC| Business
REDWOOD CITY, Calif., April 10, 2017 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017 12:08 pm UTC| Business
REDWOOD CITY, Calif., April 10, 2017 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017 12:08 pm UTC| Business
REDWOOD CITY, Calif., April 10, 2017 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals Announces Bayer Terminates its Option to License Vantictumab or Ipafricept
Apr 10, 2017 12:08 pm UTC| Business
REDWOOD CITY, Calif., April 10, 2017 -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology...